Jolt Health Inc. (JOLT.CN)
- Previous Close
0.1100 - Open
0.0000 - Bid --
- Ask 0.1450 x --
- Day's Range
0.1100 - 0.1100 - 52 Week Range
0.0450 - 0.2000 - Volume
0 - Avg. Volume
27,604 - Market Cap (intraday)
700,093 - Beta (5Y Monthly) 2.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 22, 2018
- 1y Target Est
--
Jolt Health Inc. operates as a licensee of technologies relating to substances and pharmaceutical grade therapeutics in Canada, the Netherlands, rest of Europe, and Jamaica. The company focuses on sexual health, with or without the benefit of CBD, acquired pursuant to various licenses. It offers CannaStrip, an oral muco-adhesive strips enhance the bioavailability of hemp oil extracts and THC, increasing the impact and duration of the health benefits; Arousel Gel, a topical gel infused with CBD and/or THC that increases genital blood flow causing vaginal engorgement/lubrication and clitoral engorgement/sensitivity; and CannaMint, a patent-protected technology that uses orally dissolvable mints to deliver CBD or THC for a variety of conditions. The company also provides female sexual dysfunction supplement, a female sexual desire supplement; ToConceive, a vaginal moisturize; and male enhancement gel with CBD, a topical personal care penile gel. The company was formerly known as Love Pharma Inc. and changed its name to Jolt Health Inc. in May 2023. Jolt Health Inc. is headquartered in Vancouver, Canada.
jolt-health.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: JOLT.CN
View MorePerformance Overview: JOLT.CN
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: JOLT.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: JOLT.CN
View MoreValuation Measures
Market Cap
700.09k
Enterprise Value
851.53k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-38.06%
Return on Equity (ttm)
-860.11%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-787.34k
Diluted EPS (ttm)
-0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
274
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-195.13k